107,271 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 107,271 shares of the company’s stock, valued at approximately $15,214,000.

A number of other large investors also recently added to or reduced their stakes in NBIX. JPMorgan Chase & Co. grew its holdings in Neurocrine Biosciences by 11.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after acquiring an additional 468,405 shares during the last quarter. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after acquiring an additional 1,263,633 shares during the last quarter. Geode Capital Management LLC grew its holdings in Neurocrine Biosciences by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after acquiring an additional 34,457 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in Neurocrine Biosciences by 1.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock worth $166,258,000 after acquiring an additional 16,543 shares during the last quarter. Finally, Norges Bank bought a new stake in Neurocrine Biosciences in the 4th quarter worth $162,664,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Activity

In other news, insider Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31. Following the sale, the insider owned 16,225 shares of the company’s stock, valued at approximately $2,542,619.75. The trade was a 12.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the sale, the insider directly owned 25,846 shares in the company, valued at $4,141,821.50. The trade was a 29.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 328,984 shares of company stock worth $50,986,985. 4.60% of the stock is owned by company insiders.

Neurocrine Biosciences Trading Down 2.1%

Shares of NBIX opened at $163.88 on Friday. The firm’s 50-day moving average price is $142.73 and its 200-day moving average price is $139.71. The firm has a market capitalization of $16.48 billion, a price-to-earnings ratio of 25.25, a PEG ratio of 1.23 and a beta of 0.40. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $169.57.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NBIX. Citigroup raised their price target on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Wedbush raised their price target on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Wolfe Research began coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $175.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. Finally, Piper Sandler raised their price target on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $187.52.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.